Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

PHASE2CompletedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

February 15, 2023

Study Completion Date

February 15, 2023

Conditions
Pneumococcal Vaccines
Interventions
BIOLOGICAL

24-Valent Pneumococcal Conjugate Vaccine

0.5 ml dose of VAX-24 will be administered into the deltoid muscle at Day 1

BIOLOGICAL

Pneumococcal 20-valent Conjugate Vaccine

0.5 ml dose of Prevnar 20 will be administered into the deltoid muscle at Day 1

Trial Locations (20)

22911

Charlottesville Medical Research, Charlottesville

27804

Accellacare of Rocky Mount, Rocky Mount

29405

Coastal Carolina Research, North Charleston

29464

Accellacare of Charleston, Mt. Pleasant

30038

Pivotal Research Solutions, Stonecrest

31406

Meridian Clinical Research, Savannah

32720

Accel Research Sites - DeLand Clinical Research Unit, DeLand

33024

CenExel RCA, Hollywood

33351

Precision Clinical Research, Sunrise

35216

Accel Research Sites-Birmingham Clinical Research Unit, Birmingham

45219

Meridian Clinical Research, Cincinnati

60422

Healthcare Research Network II, LLC, Flossmoor

63042

Healthcare Research Network, Hazelwood

67114

AMR Newton, formerly Heartland Research Associates, Newton

67205

AMR Wichita West, Wichita

68134

Meridian Clinical Research, Omaha

70119

AMR New Orleans, New Orleans

78229

Clinical Trials of Texas, LLC, San Antonio

84088

Velocity Clinical Research, Salt Lake City, West Jordan

84107

CenExel JBR Clinical Research, Salt Lake City

All Listed Sponsors
lead

Vaxcyte, Inc.

INDUSTRY